Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001178913-22-000040
Filing Date
2022-01-05
Accepted
2022-01-05 16:02:54
Documents
6
Period of Report
2022-01-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A zk2227012.htm DEF 14A 306028
2 image00003.jpg GRAPHIC 6777
3 sc2.jpg GRAPHIC 2276
4 sc3.jpg GRAPHIC 1742
5 sc4.jpg GRAPHIC 5537
6 sc.jpg GRAPHIC 4665
  Complete submission text file 0001178913-22-000040.txt   336651
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38807 | Film No.: 22511064
SIC: 2834 Pharmaceutical Preparations